Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane
Completed
Pfizer
Phase 3
2001-08-01
To compare the effects of exemestane for 5 years versus tamoxifen and exemestane given
sequentially over 5 years in the adjuvant treatment of postmenopausal women with early breast
cancer.
This Pfizer sponsored trial is part of an international collaboration of investigators
conducting 7 similar yet independent studies in 9 countries. This study is designed to be
part of the larger TEAM trial where the data from these 7 studies will be combined. A
pre-specified analysis of the pooled data will be conducted.
Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen
Completed
Pfizer
Phase 2
2002-01-01
This is an open-label, multicenter, randomized (1:1 randomization ratio) study of either
exemestane or exemestane plus celecoxib in postmenopausal women with ABC having progressed on
tamoxifen.
Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal Women
Terminated
Pfizer
Phase 2
2002-06-01
The purpose of this study is to find out if the two different formulations of exemestane
(Aromasin), oral and injectable, are equivalent in terms of pharmacodynamics and
pharmacokinetics, i.e., if ultimately both formulations have the same efficacy in
postmenopausal women with metastatic breast cancer who have failed previous antiestrogens
therapy and are equally safe.
The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer
Completed
AstraZeneca
Phase 3
2003-08-01
The purpose of this study is to compare the efficacy of Faslodex (fulvestrant) to Aromasin
(exemestane) in hormone receptor positive postmenopausal women with advanced breast cancer.
Patients will be treated until disease progression or until the investigator has determined
that treatment is not in the best interest of the patient, whichever occurs first.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
